使用氨酸与Plavix结合的抗凝药疗法的有效性,在Rex分流后
JinShan Zhang1,2, Long Li1,2
1Department of General Surgery, Capital Institute of Pediatrics, Beijing, China.
Frontiers in pediatrics
|February 20, 2024
概括
氨酸与Plavix结合,有效地维持了Rex分流通道在患有肝外门静脉阻塞 (EHPVO) 的儿童中的通透性. 这种抗凝药疗法改善了入口血液流入肝脏的流量,提高了手术结果.
科学领域:
- 儿科手术 儿科手术
- 血管外科 血管外科
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝外门静脉阻塞 (EHPVO) 是儿童的一种严重疾病.
- 雷克斯分流是EHPVO的最佳外科治疗方法.
- 保持旁路静脉通透性对于雷克斯分流成功至关重要.
研究的目的:
- 为了研究用肝素和Plavix治疗抗凝固剂疗法的有效性.
- 评估雷克斯分流手术后对预后和分流通透性的影响.
- 为了评估患有EHPVO的儿童的结果.
主要方法:
- 一项对51名儿童进行的回顾性研究,这些儿童接受了EHPVO的Rex分流.
- 抗凝剂组 (肝素+普拉维克斯) 与非抗凝剂组之间的比较.
- 手术后的超声波测量绕道静脉流量,并计算绕道静脉流量指数 (BVFI).
主要成果:
- 抗凝剂组的BVFI显著更高 (5.71 ± 5.89对1.1 ± 1.52,P=0.003).
- 所有经历再次出血的8名患者都属于非抗凝剂组.
- 在高缩症或静脉缩症缓解率上没有显著差异,但在抗凝剂组中,术后高缩症病例较少.
结论:
- 氨酸与Plavix相结合,对于保持Rex分流旁路静脉通透性至关重要.
- 抗凝固药物治疗改善了Rex分离后入口血液流入肝脏的流量.
- 这种疗法改善了EHPVO儿童的整体预后,这些儿童接受了Rex shunt.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K


